Trump and the DEA's Marijuana Reclassification – MacIver Institute
Latest News
Steil Wants Federal “Baseline Requirements” for Future Elections
January 30, 2026 | Benjamin Yount
MacIver Applauds Congressman Steil, MEGA Election Reforms
January 29, 2026 | MacIver Staff
Wanggaard: Ending Lincoln Hills Consent Decree is Good, Closing it Better
January 29, 2026 | Benjamin Yount
Trump Endorses Tiffany in GOP Race for Wisconsin Governor
January 28, 2026 | Benjamin Yount
Tiffany Targets 400-Year Veto as Centerpiece of Property Tax Plan
January 27, 2026 | Benjamin Yount
Mnookin Leaves UW-Madison, Will Become Columbia University President
January 26, 2026 | Benjamin Yount
Stay Informed
Get updates in your inbox on the latest news and analysis from the MacIver Institute.
An Exclusive Evening with Tucker Carlson
SPEAKERS
Tucker Carlson
A sign of things to come?
In a move that has shaken up the landscape of drug policy, President Trump and the U.S. Drug Enforcement Administration (DEA) recently reclassified marijuana from Schedule I to Schedule III under the Controlled Substances Act. This shift acknowledges the plant’s potential benefits and lower risk of abuse compared to its previous categorization alongside substances like heroin. This development presents opportunities for economic freedom and innovation; however, it also raises concerns about government overreach, market distortions, and unintended societal costs.
At its core, the reclassification reduces federal barriers to create legitimate commerce. For decades, marijuana’s Schedule I status stifled research, banking, and business operations, forcing entrepreneurs into a gray area vulnerable to inconsistent state and federal laws and federal threats. Now, as a Schedule III substance, cannabis can be prescribed by doctors, studied more freely in clinical trials, and potentially integrated into mainstream pharmaceuticals. This opens the door for private enterprises to innovate—developing new treatments for conditions like chronic pain, epilepsy, and nausea—without the constant fear of federal interference.
The reclassification of marijuana from Schedule I to Schedule III recognizes its medical benefits and lower abuse potential, removing major federal obstacles to Wisconsin establishing a regulated medical cannabis program. This could generate approximately $165 million in annual tax revenue, according to the Legislative Fiscal Bureau while creating thousands of jobs in cultivation, processing, retail, and research. Businesses would gain access to standard banking and tax deductions (eliminating IRS Section 280E penalties), improving profitability and reducing enforcement costs, potentially yielding over $1 billion in net economic benefits over five years through increased state income, agricultural output, and related industry growth.
Pharmaceutical companies, startups, and even small-scale growers could vie for consumers’ dollars, fostering job creation and economic growth. States like Wisconsin, which have lagged in legalization efforts, may see an influx of investment as businesses relocate to more favorable regulatory environments. The MacIver Institute has long advocated for policies that empower individuals and limit government interference; in this vein, reclassification could dismantle the prohibitions that have propped up black markets and enriched criminal cartels.
However, free-market advocates must remain vigilant against the pitfalls that often accompany such policy shifts. History shows that when the government “liberalizes” a market, it rarely does so without strings being attached. The reclassification doesn’t equal full decriminalization—marijuana remains controlled, subject to FDA approvals, DEA oversight, and potential new taxes. We’ve seen this playbook before with alcohol and tobacco: initial deregulation gives way to burdensome regulations, sin taxes, and public health mandates that distort markets and burden taxpayers.
Take public health costs, for instance. Data from states like Colorado, where recreational marijuana has been legal since 2014, reveal spikes in impaired driving incidents and emergency room visits related to cannabis use.
These externalities—higher insurance premiums, strained healthcare systems, and lost productivity—often fall on the public dime, violating the tenet that individuals should bear the costs of their choices. If federal reclassification leads to broader access without corresponding personal responsibility measures, it could exacerbate these issues nationwide. Moreover, the push toward medical marijuana, as seen in recent Wisconsin Senate proposals, risks creating crony capitalist structures.
Bills that license a limited number of growers and dispensaries—often favoring well-connected insiders—stifle true competition and drive up prices for consumers. From a free-market standpoint, this is antithetical to open markets; we’d be better served by full deregulation, allowing supply and demand to dictate the industry without artificial barriers. Wisconsin’s own debates highlight these tensions. Republican-led efforts to introduce medical marijuana emphasize private-sector involvement, which is a step in the right direction.
As Governor Evers and Democrats advocate for broader reforms, including recreational use, free-market proponents must insist on safeguards that protect liberty without subsidizing vices. Ultimately, the reclassification of marijuana presents a test for free-market ideals. It could unleash the entrepreneurial spirit and increase freedom, allowing adults to make informed choices in a competitive marketplace. But without careful guardrails—such as minimal taxation, robust enforcement against impaired driving, and resistance to regulation—it risks turning into another government-managed disaster.
In the end, progress is found not in reclassifying substances but in changing the government’s role: from overseer to enabler of free exchange. Only then can we reap the benefits of innovation while avoiding the traps of dependency and distortion.
ABOUT THE AUTHOR
Dylan Wilder
Dylan Wilder is a creative designer, videographer, and writer at MacIver and received his bachelor’s degrees in education and business from Carroll University.
Interested in the content of this Article?
Reach out to the MacIver Institute to aquire more information
Stay Informed
Get updates in your inbox on the latest news and analysis from the MacIver Institute.
Signup to get updates in your inbox on the latest news and analysis from the MacIver Institute.
44 E Mifflin, Suite 404
Madison, WI 53703
Phone: 855-MACIVER
info@maciverinstitute.com
© 2026 The John K. MacIver Institute for Public Policy, Inc. All Rights Reserved.
Website Design By Rockstar Design
Rockstar Design is a MODX Professional Partner
Sign up to our email list
Signup to get updates in your inbox on the latest news and analysis from the MacIver Institute.
Search
CONTENT SEARCH
AUTHOR SEARCH
TOP ARTICLE TAGS
Introduction
By providing your phone number, you agree to receive SMS/text messages from MacIver Institute. Message frequency varies. Text “STOP” to stop receiving messages or “HELP” for assistance.
Opt-In
When you opt-in to the service, you agree to receive SMS messages from MacIver Institute such as updates, issue awareness, events, and calls to action.
Message and Data Rates
Message and data rates may apply for any messages sent to you from us and to us from you. If you have any questions about your text plan or data plan, contact your wireless provider.
Frequency of Messages
Message frequency may vary. Expect periodic messages, not exceeding 10 messages per month.
How to Opt-Out
You can cancel the SMS service at any time. Just text “STOP” to the number we text you from. After you send the SMS message “STOP” to us, we will send you a reply to confirm that you have been unsubscribed. After this, you will no longer receive SMS messages from us.
How to Get Help
If you are experiencing any issues, you can get help by texting “HELP” to the number we text you from. You can also reach us at info@maciverinstitute.com.
Carriers
We are not liable for any delays in the receipt of any SMS messages, as delivery is subject to effective transmission from your network operator. MacIver Institute’s supported carriers include all major US carriers.
Privacy
We are committed to protecting your privacy. Our use of your personal information is described in our Privacy Policy here: Our data comes from opt-in on this website and is for MacIver Institute. No mobile information will be shared with third parties/affiliates for marketing/promotional purposes. This data will only be used by Wis MacIver Institute team members. No mobile information will be soliciting donations; the focus will be on providing voting information. By agreeing to these Terms, you acknowledge that you have read and understand our Privacy Policy.
Changes to Terms
We reserve the right to change these terms and conditions at any time. If we make changes, we will post the revised terms and conditions on our website, and they will become effective immediately.
Contact Information
For any questions or concerns, please contact us at info@maciverinstitute.com.
Article of Interest
January 28, 2026 | Dylan Wilder
Trump and the DEA’s Marijuana Reclassification
Thank you for your interest in this article. Complete the form below and a MacIver Institute representative will be in touch as soon as possible.
The John K. MacIver Institute for Public Policy is a Wisconsin-based think tank that promotes free markets, individual freedom, personal responsibility and limited government. © 2024 The John K. MacIver Institute for Public Policy, Inc. All Rights Reserved.